Transforming neurological diagnostics through advanced AI decision support
A fundamental paradox exists in modern neurology: while therapeutic innovation has delivered advanced treatments, the diagnostic pathway remains archaic, fragmented, and unacceptably slow. This disconnect significantly reduces treatment value due to delays in initiation.
Global stroke management market projected growth from $41.7B in 2024
Therapeutics and diagnostics market forecast
Diagnosis and therapeutics market growth
The current patient journey spans months with significant diagnostic delays. Patients are passed between specialists, undergoing disconnected tests that create a data-rich but insight-poor environment where critical patterns can be overlooked.
In stroke, every minute of delay leads to the death of millions of neurons. The mantra "time is brain" is a clinical reality with devastating consequences.
For progressive diseases like Alzheimer's, the window for effective intervention occurs long before severe symptoms manifest. By the time diagnosis is certain, significant and irreparable cognitive decline has already occurred.
Diagnostic delays impose a staggering economic burden on healthcare systems through:
The existing diagnostic infrastructure is fundamentally ill-equipped to handle the impending wave of aging patients.
GoodMind introduces a secure, cloud-based diagnostic intelligence engine that empowers clinicians with enhanced insights. Our platform unifies fragmented patient data and transforms it into a coherent, actionable clinical picture.
CT/MRI decision support for acute stroke and dementia detection with rapid turnaround in minutes
Planned integration of EHR, biomarkers, genomics, and cognitive signals as partnerships mature
Designed to integrate with existing EMR and PACS systems within clinical workflows
GoodMind integrates seamlessly into existing acute stroke workflows, supporting clinicians at critical decision points without disrupting established protocols.
Patient presents with suspected stroke; emergency CT or MRI scan performed following standard protocols
Scan securely uploaded to GoodMind platform (V1: manual upload; V2+: automated PACS routing)
Platform generates triage flag, confidence score, and visual attention maps highlighting regions of interest
Qualified professional reviews scan alongside GoodMind outputs; clinician makes final diagnostic determination
Case routed appropriately based on clinical judgment: immediate consultation, standard workflow, or additional assessment
The fundamental flaw in current diagnostics is its reliance on siloed, single-modality analysis. GoodMind shatters these data silos with Multimodal AI Synthesis, creating a comprehensive biological narrative.
Non-contrast CT and structural MRI analyzed for subtle imaging patterns in tissue intensity and texture. This is our core initial product offering, delivering proven value from neuroimaging alone.
Roadmap includes incorporating fMRI and PET to further refine diagnostic signals, once partner data rights and governance are established.
Integration of genetic risk scores, specific gene variants (e.g., APOE4 for Alzheimer's), and fluid biomarker levels, contingent on partner data access and ethical approvals.
Incorporation of digital cognitive assessments and passive data from smart devices to capture subtle declines long before they become clinically obvious.
Our platform accelerates diagnostic workflows, translating directly into:
GoodMind is built on Google Cloud Platform (GCP), providing the three pillars essential for mission-critical healthcare solutions.
GCP's elastic infrastructure dynamically scales computational resources. Whether processing ten scans or ten thousand, our platform maintains optimal performance without bottlenecks.
Leveraging Google's global network and redundant systems guarantees high availability and uninterrupted service for clinical tools practitioners depend on.
Healthcare-grade security controls with encryption, role-based access, comprehensive audit logs. Supports HIPAA, GDPR, PDPA compliance. Working toward ISO 13485 and ISO 27001 certification.
Secure upload application for fastest path to pilot
PACS routing integration for automated DICOM ingestion
Deeper workflow integration including viewer integration and structured reporting
GoodMind's neuroimaging-first platform has produced multiple validated model families for dementia and stroke imaging tasks, demonstrating strong within-dataset performance and critical cross-dataset generalization.
Within-dataset validation accuracy on OASIS-derived dataset
Average accuracy across dataset holdout scenarios for dementia classification
Accuracy on combined CT stroke dataset (normal, bleeding, ischemia)
Paradigm Shift to Multimodal Analysis
While competitors focus on single-modality diagnostics, GoodMind's platform is designed to evolve toward models trained on complementary signals including cognitive performance, imaging, and clinical records. This holistic approach enables significantly earlier and more precise diagnoses.
Proprietary Data Flywheel
Actively building high-dimensional datasets by partnering with healthcare providers in emerging markets. More diverse data leads to more robust models, which attract more partners, creating a self-perpetuating network effect competitors cannot replicate.
Foundational Model for Brain Health
Building the world's first foundational model for brain health—a large-scale, pre-trained model serving as the core intelligence layer for a vast ecosystem of neurological and psychiatric applications, from screening to treatment planning to drug discovery.
Cloud-first product supporting emergency and stroke workflows using non-contrast CT:
Initial focus on emerging markets (GCC/Middle East, Pakistan, Indonesia, Philippines) with:
SaaS (per site/network): Annual subscription by sites + volume tiers + modules. Predictable budgets and SLAs for enterprise buyers.
Per-scan (usage-based): $ per processed scan with volume discounts. Low friction adoption for imaging networks.
Hybrid: SaaS base + per-scan overage for mixed networks.
USA:
600 Congress Ave, Austin, TX 78701,
T: (+1) 512 998 1584
UK:
Floor 3, 50 – 60 Station Rd,
Cambridge CB1 2JH, United Kingdom
UAE:
One Central 8th and 9th Floor
-Trade Centre – Trade Centre 2 – Dubai
Indonesia:
Mampang Business Park Unit A-01, Jl. Tutty Alawiyah, South Jakarta, Indonesia
© 2026 GOODFOLIO LTD
GOODFOLIO Ltd is Registered in England & Wales Company Number 13402423.
All rights reserved.
AI-Powered Early Detection of Brain Disorders